Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.

Lore Vanderbeke Nico A F Janssen Dennis C J J BergmansMarc BourgeoisJochem B Buil Yves Debaveye Pieter Depuydt Simon Feys Greet HermansOscar HoitingBen van der HovenCato JacobsKatrien Lagrou Virginie Lemiale Piet Lormans Johan A MaertensPhilippe MeerssemanBruno Mégarbane Saad Nseir Jos A H van Oers Marijke Reynders Bart J A Rijnders Jeroen A Schouten Isabel Spriet Karin Thevissen Arnaud W Thille Ruth Van Daele Frank L van de Veerdonk Paul E Verweij Alexander Wilmer Roger J M Brüggemann Joost Wautersnull null

Published in: Intensive care medicine (2021)

The higher than expected incidence of early IAPA precludes any definite conclusion on POS prophylaxis. High mortality of early IAPA, despite timely antifungal therapy, indicates that alternative management strategies are required. After 48 h, still 11% of patients developed IAPA. As these could benefit from prophylaxis, differentiated strategies are likely needed to manage IAPA in the ICU.

Keyphrases